Clinical trial
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate…
NCT00223145 · Abdenour Nabid, Other · Active, not recruiting
Key facts
| NCT number | NCT00223145 |
|---|---|
| Title | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone |
| Official title | Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy |
| Acronym | PCS III |
| Lead sponsor | Abdenour Nabid, Other |
| Collaborators | AstraZeneca Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade |
| Enrollment | 600 |
| Start date | Dec 1, 2000 |
| Primary completion | Dec 31, 2026 |
| Completion | Dec 31, 2027 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 27, 2025 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: